TSC2 and lymphangioleiomyomatosis: Inhibitors of the mTORC1 pathway have been shown to have therapeutic benefits in LAM and other TSC manifestations; however, there is a need for continuous therapy for persistent benefit, since mTORC1 inhibitors have cytostatic, and not cytotoxic, effects on TSC2-deficient cells (17, 18).